NCT00475371View on ClinicalTrials.gov

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2007

Conditions
Diabetes Mellitus, Type 2Healthy Males
Interventions
DRUG

MKC253 Inhalation Powder

Inhalation powder

Trial Locations (1)

9470 AE

University Medical Centre Groningen, Zuidlaren

Sponsors
All Listed Sponsors
lead

Mannkind Corporation

INDUSTRY